|
Title
|
|
|
|
Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Although normally restricted to activated T and B cells and mature dendritic cells, constitutive expression of CD70, a member of the tumor necrosis family, has been described in both hematological and solid tumors, where it increases tumor cell and regulatory T cell survival by signaling through its receptor, CD27. We have assessed the co-expression of CD70 and CD27 in non-small cell lung cancer (NSCLC) by immunohistochemistry to explore a correlation between expression of the protein and tumor histologic subtype, genetic aberrations and prognosis. Furthermore, we tested the ability of ARGX-110, a CD70-blocking antibody, to induce NK cell-mediated cytotoxicity. Our results revealed CD70 expression on the surface of both primary and metastatic NSCLC tumor cells and in the tumor microenvironment. Moreover, CD27-expressing tumor infiltrating lymphocytes were found adjacent to the tumor cells, suggesting active CD70-mediated signaling. Finally, we have shown that ARGX-110, has potent cytotoxic effects on CD70(+) NSCLC cell lines. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Oncotarget. - Albany, N.Y, 2010, currens
| |
|
Publication
|
|
|
|
Albany, N.Y
:
Impact Journals
,
2015
| |
|
ISSN
|
|
|
|
1949-2553
| |
|
DOI
|
|
|
|
10.18632/ONCOTARGET.3880
| |
|
Volume/pages
|
|
|
|
6
:15
(2015)
, p. 13462-13475
| |
|
ISI
|
|
|
|
000359009400045
| |
|
Pubmed ID
|
|
|
|
25951351
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|